
|Videos|January 14, 2015
Important Considerations in Iron Chelation Therapy
Advertisement
Episodes in this series

Any patient receiving regular blood transfusions will need to have the excess iron in their body removed, says Thomas D. Coates, MD. For patients who receive iron chelation therapy, careful monitoring is critical, as renal and neurologic side effects can occur. Iron chelation therapy can also result in low white blood cell counts, adds Coates. In children, it is important to recognize that iron is essential to their growth and development.
In Coates’ opinion, regulating the dose of an iron chelating agent should be based more on tolerance for the medication than on the body’s iron levels. Poor adherence remains an issue with these agents, adds Coates.
Advertisement
Related to this article

The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.

Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.

Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.

Mipletamig plus venetoclax and azacitidine produced a CBR of 93% in induction-ineligible, TP53-mutated acute myeloid leukemia.

Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.

Pegylated G-CSF produced rates of successful CD34-positive cell collection and safety comparable to daily G-CSF in healthy allogeneic transplant donors.

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5

























